Frovatriptan indications and usage: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi (talk | contribs) mNo edit summary |
Gerald Chi (talk | contribs) mNo edit summary |
||
Line 20: | Line 20: | ||
{{FDA}} | {{FDA}} | ||
[[Category:Antimigraine drugs]] | |||
[[Category:Triptans]] | [[Category:Triptans]] | ||
[[Category:Cardiovascular Drugs]] | [[Category:Cardiovascular Drugs]] | ||
[[Category:Drugs]] | [[Category:Drugs]] |
Revision as of 22:28, 9 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]
Indications and Usage
FROVA is indicated for the acute treatment of migraine with or without aura in adults.
Limitations of Use
- Use only if a clear diagnosis of migraine has been established. If a patient has no response for the first migraine attack treated with FROVA, reconsider the diagnosis of migraine before FROVA is administered to treat any subsequent attacks.
- FROVA is not indicated for the prevention of migraine attacks.
- Safety and effectiveness of FROVA have not been established for cluster headache.[1]
References
Adapted from the FDA Package Insert.